In 2015, AbbVie acquired Pharmacyclics for about $21 billion to gain rights to the portion of sales for Imbruvica, a new cancer drug that Johnson & Johnson (JNJ +0.96%) already owned part of. AbbVie's ...

In an important step toward driving long-term affordability and access to treatments for chronic and complex conditions, Evernorth Health Services Evernorth Health, a wholly owned subsidiary of Cigna ...

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. In a unique challenge to drug makers, the Dutch Pharmaceutical ...

Add Yahoo as a preferred source to see more of our stories on Google. North Chicago-based drugmaker AbbVie must pay back Medicare for raising the price of its blockbuster drug Humira too quickly, the ...

(Reuters) - Cigna said on Monday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey ...

This year, CVS Health plans to employ the classic "out with the old, in with the new" mantra when it comes to AbbVie’s Humira. Come April 1, the branded drug will be replaced by cheaper biosimilars ...

The best-selling drug Humira (adalimumab) now faces competition in the United States after a 20-year monopoly. The first adalimumab biosimilar, Amjevita, launched in the United States this past ...

Pharmaceutical giant AbbVie (NYSE: ABBV) is known for its top-selling drug Humira and its lucrative dividend that yields more than 4% at the current share price. This week Humira, which treats ...

No more waiting: Humira’s judgment day has finally arrived. The first Humira biosimilar, Amgen’s Amjevita, is set to reach the market Tuesday and kick off a tsunami-sized wave of competition. With ...

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. As of today, July 1st, Cyltezo (adalimumab-adbm) is commercially ...

Blue Shield of California is shaking up the pharmacy landscape with a landmark deal to drastically reduce the price of a biosimilar alternative to AbbVie Inc.’s (NYSE:ABBV) Humira, one of the world’s ...